Cingulate grants 20,000 stock options to director

Cingulate Inc. reported that director Lawrence Bryan Jay received a grant of 20,000 Stock Options on 2026-07-16.

Rhea-AI Filing Summary

Cingulate Inc. reported that director Lawrence Bryan Jay received a grant of 20,000 Stock Options on 2026-07-16. The options cover 20,000 shares of Common Stock at an exercise price of $4.43 per share, expire on 2036-07-16, and vest on the earlier of the one-year anniversary of grant or the 2027 annual meeting of stockholders. Following this award, Jay holds 20,000 derivative securities directly.

Insider Trade Summary

Grant/Award: 20,000 shares

Grant/Award 1 txn

Insider Lawrence Bryan Jay

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to Buy) F1	20,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to Buy) — 20,000 contracts (Direct)

Footnotes (1)

1. F1. The option vests on the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Cingulate Inc. 2027 annual meeting of stockholders.

Key Figures

Options granted: 20,000 shares Exercise price: $4.4300 per share Underlying common shares: 20,000 shares +1 more

4 metrics

Options granted 20,000 shares Stock Option award to director Lawrence Bryan Jay on 2026-07-16

Exercise price $4.4300 per share Conversion or exercise price of the Stock Option grant

Underlying common shares 20,000 shares Common Stock underlying the Stock Option (right to buy)

Expiration date 2036-07-16 Expiration of the Stock Option grant to Lawrence Bryan Jay

Key Terms

Stock Option (right to Buy), conversion or exercise price, vests, annual meeting of stockholders

4 terms

Stock Option (right to Buy) financial

"security_title is listed as "Stock Option (right to Buy)" for the grant"

conversion or exercise price financial

"The conversion_or_exercise_price field shows 4.4300 for the option"

vests financial

"The option vests on the earlier of the one-year anniversary or the 2027 meeting"

annual meeting of stockholders regulatory

"The vesting is tied to the Cingulate Inc. 2027 annual meeting of stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Cingulate (CING) report for Lawrence Bryan Jay?

Cingulate reported a grant of 20,000 stock options to director Lawrence Bryan Jay on 2026-07-16. These derivative securities relate to Common Stock and represent a compensation award rather than an open-market purchase or sale of existing shares.

How many stock options were granted to Lawrence Bryan Jay at Cingulate (CING) and at what price?

Lawrence Bryan Jay was granted 20,000 stock options covering 20,000 Common shares with a $4.43 exercise price per share. This price is the conversion or exercise price specified for the Stock Option (right to buy).

When do Lawrence Bryan Jay’s Cingulate (CING) stock options vest?

The options vest on the earlier of (i) the one-year anniversary of the 2026-07-16 grant date and (ii) the date of Cingulate Inc.’s 2027 annual meeting of stockholders, according to the grant footnote.

When do the granted Cingulate (CING) stock options to Lawrence Bryan Jay expire?

The granted stock options expire on 2036-07-16. This gives Lawrence Bryan Jay a ten-year term from the grant date during which he can choose to exercise the options at the stated $4.43 per-share exercise price.

Does this Cingulate (CING) Form 4 show a stock purchase or sale by Lawrence Bryan Jay?

No. The Form 4 reports a grant/award acquisition of 20,000 stock options, not a market purchase or sale of Common Stock. The transaction code is “A,” indicating a compensatory award rather than a discretionary trade.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/20/2026 - 07:32 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lawrence Bryan Jay

(Last) (First) (Middle)

1901 W. 47TH PLACE

(Street)

KANSAS CITY KANSAS 66205

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cingulate Inc. [ CING ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to Buy)	$4.43	07/16/2026		A		20,000		(1)	07/16/2036	Common Stock	20,000	$0	20,000	D

Explanation of Responses:

1. The option vests on the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Cingulate Inc. 2027 annual meeting of stockholders.

	/s/ Shane J. Schaffer, Attorney-in-Fact	07/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)